Market Place
Sourcing Support
Horizon`s Biologics Tepezza Receives Suppl Approval in US
09 Sep 2025 //
FDA
Horizon’s Biologics Tepezza Receives Suppl Approval in US
26 Aug 2025 //
FDA
Amgen’s Biologics Avsola Recieves Suppl Approval in US
25 Aug 2025 //
FDA
Amgen’s Biologics Repatha Receives Suppl Approval in US
21 Aug 2025 //
FDA
Amgen`s Tepezza Receives Approval in Europe
19 Jun 2025 //
EMA
Immunex`s Biologics Enbrel Receives Suppl Approval in US
18 Jun 2025 //
FDA
Amgen`s Biologics Amjevita Receives Suppl Approval in US
20 May 2025 //
FDA
Amgen`s Biologic Blincyto Receives Approval in US
29 Apr 2025 //
FDA
Amgen`s Biologic Bkemv Receives Suppl Approval in US
18 Apr 2025 //
FDA
Leo Pharma`s Tepezza Approved in Canada
17 Apr 2025 //
HEALTH CANADA
Amgen Inc`s Pavblu Receives Approval in Europe
04 Apr 2025 //
EMA
Amgen`s Biologic Kanjinti Receives Suppl Approval in US
19 Dec 2024 //
FDA
Amgen`s Biologic Repatha Receives Suppl Approval in US
20 Nov 2024 //
FDA
Amgen`s Biologic Repatha (Evolocumab) Receives Suppl Approvals in US
19 Aug 2024 //
FDA
Amgen`s Biologic Amjevita (Adalimumab) Receives Suppl Approvals in US
19 Aug 2024 //
FDA
Immunex`s Biologic Enbrel(Etanercept) Receives Suppl Approval in US
22 Jul 2024 //
FDA
Amgen`s Wezenla (ustekinumab) Receives Approval in Europe
18 Jul 2024 //
EMA
Amgen Biologic Blinatumomab Receives Suppl Approval in US
14 Jun 2024 //
FDA
Amgen`s Biologic mdelltra (tarlatamab-dlle) Receives Approval in the U.S.
16 May 2024 //
FDA
Amgen`s Prolia (denosumab) Receives Suppl Approval in the U.S.
09 Apr 2024 //
FDA
Amgen`s Xgeva (denosumab) Receives Approval in the U.S.
09 Apr 2024 //
FDA
Amgen`s Biologic Blincyto (blinatumomab) Receives Approval in the U.S.
08 Feb 2024 //
FDA
Amgen`s Biologic Amjevita (adalimumab) Receives Approval in the U.S.
14 Aug 2023 //
FDA
Horizon`s Biologic Tepezza(teprotumumab) Receives Approval in the U.S.
17 Jul 2023 //
FDA
Amgen`s Biologic Blincyto (Blinatumomab) Receives Approval in the U.S.
20 Jun 2023 //
FDA
Amgen`s Biologic Amjevita (Adalimumab) Receives Approval in the U.S.
06 Apr 2023 //
FDA
Amgen`s Biologic Prolia (Denosumab) Receives Approval in U.S.
03 Jan 2023 //
FDA
Horizon`s Biologic TEPEZZA (Teprotumumab) Receives Approval in the U.S.
06 Dec 2022 //
FDA
Amgen`s Biologic BLINCYTO (Blinatumomab) Receives Approval in the U.S.
05 Dec 2022 //
FDA
Horizon`s Uplizna Receives Approval in Europe
30 Nov 2022 //
EMA
Amgen`s Biologic Aimovig (Erenumab) Receives Approval in the U.S.
03 Oct 2022 //
FDA
Immunex`s Biologic Enbrel (Etanercept) Receives Approval in the U.S.
16 Aug 2022 //
FDA
Amgen`s Biologic Aimovig (Erenumab-Aooe) Receives Approval in the U.S.
15 Aug 2022 //
FDA
Amgen Amjevita (adalimumab-atto) Receives BLA Approval in the U.S.
28 Jul 2022 //
FDA
Amgen Riabni (rituximab-arrx) Receives Supplemental Approval in the U.S
03 Jun 2022 //
FDA
Amgen`s Biologic Blincyto (Blinatumomab) Receives Approval in the U.S.
18 Feb 2022 //
FDA
Amgen`s Biologic Nplate (Romiplostin) Receives Approval in the U.S.
10 Feb 2022 //
FDA
Amgen`s Mvasi (bevacizumab-awwb) Receives Supplemental Approval in Europe
19 Nov 2021 //
FDA
Amgen`s Imlygic (talimogene laherparepvec) Receives Approval in Europe
26 Oct 2021 //
EMA
Amgen`s Biological Evolocumab Receives Supplemental Approval In US
24 Sep 2021 //
FDA
Amgen`s Biologic Avsola Receives Approval in the US
09 Sep 2021 //
FDA
Amgen`s Biological Panitumumab Receives Approval In the US
25 Aug 2021 //
FDA
Amgen Inc`s Mvasi (Bevacizumab-awwb) Receives Supplemental Approval In US
22 Apr 2021 //
FDA
Amgen Inc`s Nplate (Romiplostim)Receives Supplemental Approval In US
13 Feb 2021 //
FDA
Amgen Inc`s Neulasta (Pegfilgrastim) Receives Supplemental Approval In US
08 Feb 2021 //
FDA
Amgen Inc`s Neupogen (Filgrastim)Receives Supplemental Approval In US
08 Feb 2021 //
FDA
Amgen Inc`s Nplate Romiplostim Receives Supplemental Approval In US
30 Jan 2021 //
FDA
Amgen Inc`s Neupogen (Filgrastim) Receives Supplemental Approval In US
09 Jan 2021 //
FDA
Amgen Inc`s Neulasta (Pegfilgrastim) Receives Supplemental Approval In US
09 Jan 2021 //
FDA
Amgen`s Riabni (rituximab-arrx) Receives Supplemental Approval In US
21 Dec 2020 //
FDA
Amgen`s Nplate (romiplostim) Receives Supplemental Approval In US
26 Nov 2020 //
FDA
Amgen`s Xgeva (Denosumab) Receives Supplemental Approval In US
16 Jun 2020 //
FDA
Amgen`s Prolia (Denosumab) Receives Supplemental Approval In US
16 Jun 2020 //
FDA
Amgen`s Repatha (Evolocumab) Receives Supplemental Approval In US
14 May 2020 //
FDA
Amgen`s Blincyto (Blinatumomab) Receives Supplemental Approval In US
24 Mar 2020 //
FDA
Amgen`s Aimovig (Erenumab aooe ) Receives Supplemental Approval In US
20 Feb 2020 //
FDA
Horizon Pharma`s Cysteamine Bitartrate Receives Approval in US
20 Feb 2020 //
FDA
Amgen`s Xgeva (Denosumab ) Receives Supplemental Approval In US
13 Feb 2020 //
FDA
Amgen`s Prolia (Denosumab ) Receives Supplemental Approval In US
13 Feb 2020 //
FDA
